Elite 50% OFF Act now – get top investing tools Register Now!

AIM ImmunoTech Inc.

Contributing Author

Recent Articles by AIM ImmunoTech Inc.

Nov-18	AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program AIM GlobeNewswire
Nov-10	AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer AIM GlobeNewswire
Nov-04	AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting AIM GlobeNewswire
Nov-03	AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue AIM GlobeNewswire
Oct-20	AIM ImmunoTech to Attend the 2025 Maxim Growth Summit AIM GlobeNewswire
Sep-25	AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors AIM GlobeNewswire
Sep-22	AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth AIM GlobeNewswire
Sep-04	AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland AIM GlobeNewswire
Aug-21	AIM ImmunoTech Announces Release of the Next CEO Corner Segment AIM GlobeNewswire
Aug-15	AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update AIM GlobeNewswire
Aug-14	AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech AIM GlobeNewswire
Aug-06	AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) AIM GlobeNewswire
Aug-04	AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval AIM GlobeNewswire
Jul-31	AIM ImmunoTech Announces Closing of $8.0 Million Public Offering AIM GlobeNewswire
Jul-29	AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering AIM GlobeNewswire
Jul-28	AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer AIM GlobeNewswire
Jul-02	AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies AIM GlobeNewswire
Jun-20	AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements AIM GlobeNewswire
Jun-17	AIM ImmunoTech Resumes Trading on NYSE American AIM GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.